Celgene Corp (CELG) 86.57 $CELG
ClearBridge Value: Making It A Top Mutual Fund Again
at Investor's Business Daily - Tue Aug 05, 5:30PM CDT
How do you follow a legend? That's been one of the challenges for Sam Peters, who has been lead manager of $2.7 billion ClearBridge Value since taking the baton from Bill Miller about two years ago. Miller -- who still runs $2.1 billion Legg Mason...
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
Final Glance: Biotechnology companies
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Celgene Falls 1.02% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.
Midday Glance: Biotechnology companies
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 05, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver
PR Newswire - Tue Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Celgene (CELG) Approaches New Upside Target of $88.55
Comtex SmarTrend(R) - Mon Aug 04, 9:08AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $86.90 and have already reached the first level of resistance at $87.60. Analysts will be watching for a cross of the next upside pivot targets of $88.55 and $90.20.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Use of Priority Review Voucher and Financial Result Releases of Healthcare Companies - Research Reports on Regeneron, WellPoint, Edwards, Humana and Celgene
PR Newswire - Mon Aug 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), WellPoint Inc. (NYSE: WLP), Edwards Lifesciences Corp. (NYSE: EW), Humana Inc. (NYSE: HUM) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5412-100free.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
ClearBridge Value: Making It A Top Mutual Fund Again
at Investor's Business Daily - Tue Aug 05, 5:30PM CDT
How do you follow a legend? That's been one of the challenges for Sam Peters, who has been lead manager of $2.7 billion ClearBridge Value since taking the baton from Bill Miller about two years ago. Miller -- who still runs $2.1 billion Legg Mason...
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
Final Glance: Biotechnology companies
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Celgene Falls 1.02% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.
Midday Glance: Biotechnology companies
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 05, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver
PR Newswire - Tue Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Celgene (CELG) Approaches New Upside Target of $88.55
Comtex SmarTrend(R) - Mon Aug 04, 9:08AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $86.90 and have already reached the first level of resistance at $87.60. Analysts will be watching for a cross of the next upside pivot targets of $88.55 and $90.20.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
Use of Priority Review Voucher and Financial Result Releases of Healthcare Companies - Research Reports on Regeneron, WellPoint, Edwards, Humana and Celgene
PR Newswire - Mon Aug 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), WellPoint Inc. (NYSE: WLP), Edwards Lifesciences Corp. (NYSE: EW), Humana Inc. (NYSE: HUM) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5412-100free.
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
